Thromboprophylaxis with LMWH, warfarin, low-dose aspirin, safe in newly diagnosed multiple myeloma

January 2010
Hem/Onc Today;1/10/2010, Vol. 11 Issue 1, p18
This article focuses on a study which investigated the efficacy and safety of thromboprophylaxis with low-molecular weight heparin, warfarin or low-dose aspirin in preventing venous thromboembolism in patients with multiple myeloma.


Related Articles

  • Aspirin, warfarin may reduce thromboembolic events in multiple myeloma.  // Hem/Onc Today;3/25/2011, Vol. 12 Issue 6, p14 

    The article reports that fixed-dose warfarin or aspirin showed comparable efficiency as low-molecular-weight heparin in cutting the risk for thromboembolic events in myeloma patients who received regimens with thalidomide, which is based on a study involving 659 patients.

  • Regimen recaptured responses in heavily pretreated multiple myeloma.  // Hem/Onc Today;10/25/2013, Vol. 14 Issue 20, p44 

    The article presents the results of a phase two study as of late October 2013, which showed that the combination of panobinostat, bortezomib and dexamethasone is effective in heavily pretreated patients with bortezomib-refractory multiple myeloma.

  • 12. Vaccination strategies in multiple myeloma.  // Hematology Journal;2003 Supplement, Vol. 4 Issue 1, pS267 

    The Hematology Journal (2003) 4, S267-S272. doi:10.1038/sj.thj.6200292

  • Melphalan and prednisone versus melphalan, prednisone and thalidomide for elderly and/or transplant-ineligible patients with multiple myeloma: a meta-analysis. Kapoor, P.; Rajkumar, S. V.; Dispenzieri, A.; Gertz, M. A.; Lacy, M. Q.; Dingli, D.; Mikhael, J. R.; Roy, V.; Kyle, R. A.; Greipp, P. R.; Kumar, S.; Mandrekar, S. J. // Leukemia (08876924);Sep2011, Vol. 25 Issue 9, p1523 

    A correction to the article "Melphalan and prednisone versus melphalan, prednisone and thalidomide for elderly and/or transplant-ineligible patients with multiple myeloma: a meta-analysis" that was published online on January 14, 2011 is presented.

  • Cytogenetic abnormalities found in multiple myeloma patients. Dale, David C.; Federman, Daniel D. // Cortlandt Forum;09/25/97, Vol. 10 Issue 9, p28 

    States that cytogenetic abnormalities can be found in multiple myeloma patients. Reason for the occurrence of abnormalities; Types of common and nonrandom abnormalities; Prognosis of patients.

  • Thalidomide approved for multiple myeloma.  // WHO Drug Information;2008, Vol. 22 Issue 1, p19 

    The article reports on the approval of Thalimodine Pharmion thalidomide drug for the treatment of multiple myeloma by the European Medicines Agency (EMEA) in Europe. EMEA has approved the drug for the treatment of bone marrow cancer multiple myeloma. Results of clinical studies prove that adding...

  • Multiple myeloma: Controlling pain, prolonging survival. Farrant, Catherine // RN;Jan87, Vol. 50 Issue 1, p38 

    Presents a case study that describes how treatment and skilled nursing care can help patients with multiple myeloma minimize complications and live more independently in the time they have left. Manifestations of the disease; Diagnosis and treatment procedures performed.

  • Cerebral toxoplasmosis in multiple myeloma. Theologides, Athanasios; Osterberg, Kenneth; Kennedy, B.J.; Theologides, A; Osterberg, K // Annals of Internal Medicine;May66, Vol. 64 Issue 5, p1071 

    Describes the occurrence of cerebral toxoplasmosis in a patient with controlled multiple myeloma. Result of postmortem examination; Information on localized cerebral toxoplasmosis; Relationship between toxoplasmosis and thyroid disease.

  • Thiotepa, busulfan, cyclophosphamide (TBC) and autologous hematopoietic transplantation: an intensive regimen for the treatment of multiple myeloma. Shimoni, A; Smith, T L; Aleman, A; Weber, D; Dimopoulos, M; Anderlini, P; Andersson, B; Claxton, D; Ueno, N T; Khouri, I; Donato, M; Korbling, M; Alexanian, R; Champlin, R; Giralt, S // Bone Marrow Transplantation;4/15/2001, Vol. 27 Issue 8, p821 

    The study was designed to evaluate the efficacy and safety of an intensive, tri-alkylator conditioning regimen, consisting of thiotepa, busulfan and cyclophosphamide (TBC), prior to autologous hematopoietic cell transplantation in patients with multiple myeloma (MM) and to analyze factors...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics